ARTICLE | Clinical News
Alagebrium: Phase IIa halted
June 13, 2005 7:00 AM UTC
ALT said FDA placed a clinical hold on enrollment in its Phase IIa EMERALD trial of alagebrium in ED due to preclinical toxicity studies showing liver alterations in rats. ALT voluntarily halted this ...